JP2017512063A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512063A5
JP2017512063A5 JP2016555527A JP2016555527A JP2017512063A5 JP 2017512063 A5 JP2017512063 A5 JP 2017512063A5 JP 2016555527 A JP2016555527 A JP 2016555527A JP 2016555527 A JP2016555527 A JP 2016555527A JP 2017512063 A5 JP2017512063 A5 JP 2017512063A5
Authority
JP
Japan
Prior art keywords
fusion protein
residue
multimeric fusion
region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555527A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851200B2 (ja
JP2017512063A (ja
Filing date
Publication date
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/054687 external-priority patent/WO2015132364A1/en
Publication of JP2017512063A publication Critical patent/JP2017512063A/ja
Publication of JP2017512063A5 publication Critical patent/JP2017512063A5/ja
Application granted granted Critical
Publication of JP6851200B2 publication Critical patent/JP6851200B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555527A 2014-03-05 2015-03-05 多量体Fcタンパク質 Expired - Fee Related JP6851200B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1403912.7 2014-03-05
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403913.5 2014-03-05
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405952.1 2014-04-02
GB1412646.0 2014-07-16
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (3)

Publication Number Publication Date
JP2017512063A JP2017512063A (ja) 2017-05-18
JP2017512063A5 true JP2017512063A5 (enExample) 2018-04-12
JP6851200B2 JP6851200B2 (ja) 2021-03-31

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555527A Expired - Fee Related JP6851200B2 (ja) 2014-03-05 2015-03-05 多量体Fcタンパク質

Country Status (15)

Country Link
US (1) US11352414B2 (enExample)
EP (1) EP3114143B1 (enExample)
JP (1) JP6851200B2 (enExample)
KR (1) KR20160130463A (enExample)
CN (1) CN106068274A (enExample)
AU (1) AU2015226100B2 (enExample)
BR (1) BR112016020368A2 (enExample)
CA (1) CA2939198A1 (enExample)
IL (1) IL247096A0 (enExample)
MX (1) MX2016010951A (enExample)
RU (1) RU2016139006A (enExample)
SG (1) SG11201606597QA (enExample)
TW (1) TW201619188A (enExample)
UY (1) UY36021A (enExample)
WO (1) WO2015132364A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Fc蛋白質
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
JP2019511458A (ja) * 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えIgG Fc多量体
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
PL3484514T3 (pl) 2016-05-23 2024-04-29 Momenta Pharmaceuticals, Inc. Kompozycje i sposoby związane z projektowanymi konstruktami Fc
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
MX2019000887A (es) 2016-07-22 2019-09-04 Gliknik Inc Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.
KR102729723B1 (ko) 2016-12-09 2024-11-15 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
JP7519774B2 (ja) 2016-12-09 2024-07-22 グリックニック インコーポレイテッド 多価fc化合物を用いる炎症性疾患の治療方法
BR112019013955A2 (pt) 2017-01-06 2020-02-11 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos de fc manipulados
CN113201071A (zh) 2017-03-28 2021-08-03 礼进生物医药科技(上海)有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー/エス オリゴマー伸長インスリン−Fcコンジュゲート
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
CN110785185B (zh) * 2017-06-05 2024-05-24 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
US20210095006A1 (en) * 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
WO2019175605A1 (en) * 2018-03-16 2019-09-19 Liverpool School Of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CA3115547A1 (en) * 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
CN114786721B (zh) * 2019-12-06 2025-10-17 康诺贝林伦瑙有限公司 Fc多聚体的稳定组合物
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业(上海)股份有限公司 一种cdc平台抗体
WO2023239940A1 (en) * 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
KR20100021601A (ko) 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Fc(ScFc) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
MX367012B (es) * 2007-06-01 2019-08-02 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
WO2010085682A2 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US8734798B2 (en) 2009-10-27 2014-05-27 Ucb Pharma S.A. Function modifying NAv 1.7 antibodies
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2849765C (en) * 2011-09-26 2021-10-19 Jn Biosciences Llc Hybrid constant regions
ES2751386T3 (es) 2011-12-21 2020-03-31 Amgen Inc Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
WO2014022592A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
AU2012392760C1 (en) 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Fc蛋白質
JP6851199B2 (ja) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Fcタンパク質
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP2018510339A (ja) 2015-03-05 2018-04-12 ユーシービー バイオファルマ エスピーアールエル 重合体Fcタンパク質及びその機能的特徴を改変するためのスクリーニング方法
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Similar Documents

Publication Publication Date Title
JP2017512063A5 (enExample)
JP2017509335A5 (enExample)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
CN103596968B (zh) 用于亲和层析的洗涤溶液和方法
JP2016526909A5 (enExample)
HRP20220080T1 (hr) Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin
JP2019522465A5 (enExample)
RU2016139006A (ru) Мультимерные fc-белки
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
JP2016525100A5 (enExample)
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
JP2020500015A5 (enExample)
RU2018138703A (ru) Слитые полипептиды cd40l-fc и способы их применения
JP2019516665A5 (enExample)
JP2014506790A5 (enExample)
JP2005120106A5 (enExample)
JP2015146822A5 (enExample)
HRP20231496T1 (hr) Cistein proteaza
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2016523959A5 (enExample)